II. Indications: As part of Combination Regimens
- Acute Myelogenous Leukemia (AML, adults)
- Acute Lymphocytic Leukemia (ALL, adults and children)
III. Mechanism
- See Antibiotic Chemotherapy
- Daunorubicin is an anthracycline Aminoglycoside antineoplastic
- Daunorubicin is isolated from the bacterium Streptomyces peucetius (or Streptomyces coeruleorubidus)
- Daunorubicin interacts with DNA via topoisomerase
- Similar clinical effects as with Doxorubicin (hydroxylated form of Daunorubicin)
- Inhibits DNA Replication and repair
- Inhibits RNA and Protein synthesis
IV. Medications
- Injection Solution: 5 mg/ml in 4 and 10 ml vials
- Combination Agents
- Daunorubicin AND Cytarabine Liposomal (Vyxeos)
V. Dosing
- See other references for disease specific dosing protocols
- Adjust dosing in renal Impairment and hepatic Impairment
VI. Adverse Effects
- Cardiotoxicity (esp. Children)
- Infusion Reaction
- Myelosuppression
- Urine Discoloration (transient red coloration)
VII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters)
- Use reliable Contraception
- Daunorubicin crosses the placenta
- Monitoring
VIII. Resources
- Daunorubicin for Injection (DailyMed)